Journal of Diabetes Research

Journal of Diabetes Research / 2014 / Article

Research Article | Open Access

Volume 2014 |Article ID 540242 |

Samira Missaoui, Khémais Ben Rhouma, Mohamed-Tahar Yacoubi, Mohsen Sakly, Olfa Tebourbi, "Vanadyl Sulfate Treatment Stimulates Proliferation and Regeneration of Beta Cells in Pancreatic Islets", Journal of Diabetes Research, vol. 2014, Article ID 540242, 7 pages, 2014.

Vanadyl Sulfate Treatment Stimulates Proliferation and Regeneration of Beta Cells in Pancreatic Islets

Academic Editor: Giuseppe Paolisso
Received23 May 2014
Revised07 Jul 2014
Accepted28 Jul 2014
Published19 Aug 2014


We examined the effects of vanadium sulfate (VOSO4) treatment at 5 and 10 mg/kg for 30 days on endocrine pancreas activity and histology in nondiabetic and STZ-induced diabetic rats. In diabetic group, blood glucose levels significantly increased while insulinemia level markedly decreased. At the end of treatment, VOSO4 at a dose of 10 mg/Kg normalized blood glucose level in diabetic group, restored insulinemia, and significantly improved insulin sensitivity. VOSO4 also increased in a dose-dependent manner the number of insulin immunopositive beta cells in pancreatic islets of nondiabetic rats. Furthermore, in the STZ-diabetic group, the decrease in the number of insulin immunopositive beta cells was corrected to reach the control level mainly with the higher dose of vanadium. Therefore, VOSO4 treatment normalized plasma glucose and insulin levels and improved insulin sensitivity in STZ-experimental diabetes and induced beta cells proliferation and/or regeneration in normal or diabetic rats.

1. Introduction

Vanadium is a transition metal. It is estimated that more than 60 thousand tons of this element is emitted into the atmosphere each year as the result of human activities mostly from the combustion of fossil fuels [1].

After entering the circulatory system via gastrointestinal or respiratory tract, vanadium compounds are transported by transferrin or, less commonly, by albumin or low molecular components of plasma, such as citrates and, to a lesser extent, lactates or phosphates [2]. Many studies were conducted on inorganic and organic vanadium derivatives in induced diabetes animal models, in which the studied compounds were found to impact the levels of glucose, cholesterol, and triglycerides, with no significant harmful side effects upon prolonged administration [37]. Many experiments were also performed in diabetic patients, confirming the therapeutic effect of vanadium compounds on blood glucose levels with little toxic effects [8].

Vanadium (including vanadyl and vanadate) has been shown to reduce blood glucose level by stimulating glycogenesis, glucose uptake, and metabolism and by inhibiting glucose formation via hepatic gluconeogenesis and glycogenolysis [9, 10]. It has been found that vanadium and vanadium compounds exhibit an insulin-like activity [9, 1113] by imitating insulin actions via insulin-receptor tyrosine kinase activation and kinase phosphorylation cascade pathways [1417]. Therefore, vanadyl sulfate has been suggested as a therapeutic agent for the treatment of type 1 diabetes [12, 1820]. Streptozotocin (STZ) treatment destroys the beta insulin-producing cells of the pancreas and STZ-induced diabetic rats are considered as a model of type 1 diabetes mellitus [21, 22]. Although vanadium compounds have been shown to have antidiabetic properties in STZ-induced diabetic model, the mechanism of their actions remained currently under investigation. The aim of this study was to investigate the responses of 30 days of treatment with vanadium sulfate in nondiabetic and STZ-induced diabetic rats.

2. Materials and Methods

2.1. Preparation of Diabetic Rats

The animals were made diabetic by an intraperitoneal injection (ip) of STZ in a single dose of 65 mg/Kg in 0.01 M citrate buffer (pH 4.5). This ip method was chosen based on recent reports which demonstrated a pronounced glucose increasing effect in STZ-diabetic rats [23, 24].

2.2. Animals and Treatment

Male Wistar rats, 5-6-week-old (weighting 175–200 g), were purchased from Pasteur Institute of Tunisia and used in accordance with the Local Ethic Committee of Tunis University for the use and care of animals in accordance with NIH recommendations. They were provided with food (standard pellet diet-Badr Utique-TN) and water ad libitum and housed five per cage under collected temperature (22°C) with a 12-hour light-dark cycle. The rats were divided into six groups.

Group 1 was nondiabetic control animals (ND control) and received daily an intraperitoneal injection (ip) of NaCl 9. Groups 2 and 3 were ND and received daily a dose of either 5 or 10 mg of VOSO4/Kg, respectively (ND + 5 mg/Kg and ND + 10 mg/Kg), for 30 days. Group 4 was a diabetic control (D control) injected with a single dose of 65 mg/Kg of STZ. Groups 5 and 6 comprised STZ diabetic animals treated with either 5 or 10 mg/Kg of VOSO4  during 30 days, respectively (D + 5 mg/Kg, D + 10 mg/Kg). STZ-groups were treated with VOSO4 after 48 hours of STZ-induced diabetes.

2.3. Biochemical Assays

All animals were fasted 12 hours before determination of glycemia by a glucometer (ACCU-CHEK-Active Roche). Insulin sensitivity was measured after ip injection of 1 U/Kg of insulin and blood glucose levels were determined at 30 min intervals during 2 hours as the percent of the hormone level at .

Animals were sacrificed after 24 hours of the last treatment and the blood was collected and serum was processed for estimation of insulin which was determined by Elisa kit (distributed by BioVendor).

2.4. Immunohistochemical Evaluation

Immunohistochemical staining of insulin was performed in order to characterize the integrity of beta cells in Langerhans islets. For this, tissue sections showing the maximum larger surface of Langerhans islets were selected for comparisons between groups. Sections were firstly deparaffined, hydrated through a decreasing gradual ethanol series, immersed in tampon citrate (pH 6) for 40 min, and then incubated with a polyclonal Guinea Pig anti-insulin antibody diluted in 50 mM Tris-HCl, pH 7,6 (DAKO). After washing, sections were incubated with phosphatase conjugated anti-Guinea Pig antibody and the procedure of revelation was assisted by TechMate 500 machine. Finally, sections were stained with haematoxylin/eosin.

Ten pancreatic islets per rat were examined under the microscope and the number of insulin-positive and insulin-negative cells was counted by numbering their nuclei. Data are expressed as the percent of insulin immunopositive cells/total number of cells in each islet.

2.5. Statistical Analysis

Significance of difference among various groups was evaluated by one-way analysis of variance (ANOVA) followed by Tukey’s Multiple Comparison test, and value was taken as significant at level.

3. Results

The effect of VOSO4  treatment on the blood glucose levels in nondiabetic (ND) and diabetic (D) rats is shown in Figure 1. There were no significant changes in the blood glucose levels in control ND group during the treatment (Figure 1(a)). Treatment of ND rats with VOSO4  at 5 or 10 mg/Kg did not change significantly the blood glucose levels during the first 10 days. However, blood glucose level decreased significantly at the end of treatment with the dose of 5 mg/Kg and was significantly reduced from 15 to 30 days with the dose of 10 mg/Kg as compared to control ND group. At day 30, the glycemia decrease was about 8 and 15%, respectively, for the doses of 5 and 10 mg/Kg compared to control group. As suspected, a notable increase of blood glucose level was observed in the STZ-treated control rats compared to untreated animals ( versus  mg/dL) indicating diabetes installation that was maintained during all experiment. Treatment of diabetic group (D) with 5 mg/Kg of VOSO4  reduced significantly blood glucose level from day 10 while a dose of 10 mg/Kg decreased blood glucose level significantly and gradually from day 5 to reach normal level at day 30. The noted values of glycemia at 30 days were and versus  mg/dL, respectively, in D + 5, D + 10, and control D groups (Figure 1(b)).

Table 1 showed the levels of insulin in ND and D groups without and following VOSO4  treatment. The ND rats treated with 5 mg/Kg of VOSO4 did not show significant changes in insulinemia level, but a marked increase was obtained with 10 mg/Kg compared to control ND group ( versus µg/L). Moreover, in control D group, insulinemia was profoundly decreased in comparison to control ND animals ( versus µg/L). Administration of VOSO4 in D groups markedly increased the insulinemia in a dose-dependent manner. In fact, insulin levels were increased in diabetic rats from to and µg/L with, respectively, 5 mg and 10 mg/Kg doses.


VOSO4 mg/Kg05100510
Insulinemia (µg/L)1.73 ± 0.041.97 ± 0.12δ δδ2.76 ± 0.07***δ δδ0.07 ± 0.01***0.49 ± 0.04***δ1.26 ± 0.12**δ δδ ππ π

: number of determination used in this experiment.
; versus ND control.
; versus D control.
versus D + 5.

Insulin sensitivities changes following the ip injection of insulin (1 U/Kg) in normal and diabetic treated animals are shown in Figure 2. In ND rats, treatment with 10 or 5 mg of VOSO4  did not alter the glycemia profile in response to insulin administration (Figure 2(a)). Indeed, in these groups, the maximum hypoglycemic effect of insulin was observed by 60 and 90 min, respectively, and was about of initial glycemia value. Diabetic animals treated with the low dose of VOSO4 showed a similar glycemia profile than control D group with a maximum decrease by 60 min while those treated with the high dose exhibited a significant () and rapid maximum decrease of glycemia by 30 min after insulin injection (Figure 2(b)).

In VOSO4  treatment groups, the size of pancreatic islets was observed to be larger compared to their respective control ND and D groups (Figures 3 and 4). Statistical analyses showed that VOSO4  treatments induced a marked increase in the number of insulin immunopositive cells by about 20% in ND + 5 and 27% in ND + 10 mg/Kg groups (Figure 5). VOSO4  treatment increased significantly the number of insulin immunopositive cells in the STZ-diabetic groups in a dose-dependent manner by 12 and 23%, respectively, with 5 and 10 mg/Kg doses (Figure 5). Comparison between STZ-diabetic treated groups and ND control rats indicated no significant differences.

4. Discussion

We studied the antidiabetic properties of vanadium by exploring its effects on blood glucose and insulin levels as well as B cells of endocrine pancreas.

Using STZ-induced diabetic rats, we showed that treatment with vanadyl sulfate (VOSO4) at 5 and 10 mg/Kg significantly reduced the mean blood glucose levels by the 10th and 5th days, respectively, in comparison with untreated control group. At day 30, diabetic rats given the higher dose of the compound exhibited similar glycemia level than ND control animals. However, in ND rats, treatment with the lower dose of VOSO4 did not change significantly the blood glucose level while the higher dose induced little and gradually decrease by the day 15 of treatment and the glycemia was decreased by about 14% at day 30. Our results are in agreement with previous data demonstrating that oral administration of vanadium compounds in STZ-induced or genetically inherited or nutritional diabetic animals significantly ameliorated hyperglycemia [2529]. In humans, Soveid et al. [30] reported the safety and the efficacy of oral vanadyl sulfate therapy during 30-month period in type 1 diabetic patients by decreasing insulin need and blood glucose level.

Our study also revealed that the hypoglycemic effect of VOSO4  was accompanied by a marked increase of basal insulinemia level in diabetic group in a dose-dependent manner. With the dose of 10 mg, the insulinemia level of diabetic rats was almost normalized. Indeed, the decrease of blood glucose levels registered particularly in diabetic rats exposed to vanadium compound may be related to the concomitant increase of plasma insulin concentrations. These results were in accordance with previous data concerning the effectiveness of vanadium compounds in ameliorating diabetic state [3032].

Further, we have investigated the effect of vanadium administration on insulin sensitivity in diabetic and nondiabetic rats. In ND groups, we showed a maximum hypoglycemic effect of insulin at 60–90 min after hormone introduction. However, in D groups, VOSO4  treatment with a dose of 10 mg enhanced insulin sensitivity with a more rapid and pronounced decrease of blood glucose following hormone injection while the dose of 5 mg did not change significantly the glycemia response of D rats. The improved insulin sensitivity induced by VOSO4 is in line with numerous studies indicating that vanadium can be considered as a potent insulin mimetic or insulin trophic in various tissues [24, 33].

It has been shown that vanadium compounds are characterized by multiple ways of action resulting in blood sugar decrease [34]. In vivo and in vitro studies reported that vanadyl sulfate increased glucose transport and metabolism in skeletal muscles, liver, and adipose tissues [25]. Thanks to their structural similarity to orthophosphate anions, the vanadium organic derivatives inhibit protein phosphotyrosine phosphatase [35]. They also inhibit the activity of PTP-1B, enzyme responsible for the dephosphorylation of insulin receptor, causing insulin resistance [36, 37]. Another mechanism of reduction of blood glucose levels by vanadium compounds is the activation of PKB/Akt kinase leading to the increase of glucose uptake by the GLUT4 transporter [34, 38]. Activation of PKB/Akt stimulates also the phosphorylation of GSK3, resulting in the stimulation of glycogen synthesis [34, 39]. On the other hand, it was found that inhibition of C-jun N-terminal kinase improves insulin sensitivity in experimental diabetes [40].

Vanadium increases glucose transport and oxidation and insulin-receptor tyrosine-kinase activity and exerts insulin-like effects on glucose and lipid metabolisms by insulin-dependent or insulin-independent biochemical pathways [9, 10, 41].

It is well known that STZ treatment destroys beta cells of pancreatic islets inducing insulin-dependent diabetes mellitus [19, 22]. Thus, in the present study, we showed a reduction in the area of pancreatic islets associated with a marked decrease in the number of immunoreactive beta cells for insulin in diabetic group in comparison with nondiabetic control animals. However, in both ND and D groups, VOSO4 treatment enlarged the size of pancreatic islets in comparison with respective control groups. Most importantly, VOSO4  treatment of diabetic rats increased in a dose-dependent manner the number of insulin immunopositive beta cells as distinguished from diabetic untreated group, suggesting that VOSO4 can generate the beta cells in STZ-induced diabetic rats. In fact, the number of beta cells in islets of diabetic VOSO4-treated rats with 5 and 10 mg was not significantly different from that of ND group. This is in agreement with previous investigations concerning the pancreatic insulinotropic property of this compound [18, 24, 42]. Interestingly, vanadium treatment also increased significantly beta cells number in islets of nondiabetic rats.

In a mouse model of pancreas alloxan-perfused segment, Waguri et al. [43] reported processes of beta cells regeneration from extra-islet precursor cells. Indeed, in STZ-diabetic rats, VOSO4 treatment might stimulate beta cells proliferation from intraislet endocrine cells and differentiation from extra-islet precursor cells.

In conclusion, the present study demonstrates that vanadyl sulfate could be useful as a potential antidiabetic agent. However, as the current evidences are still limited and based mostly on animal models and little is known about the therapeutic formulations and the side effects of vanadium compounds, further investigations on their long-term use as conventional therapy for diabetic patients are needed.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.


This work was supported by the Tunisian Ministry of Higher Education and Scientific Research.


  1. M. M. Shafer, B. M. Toner, J. T. Overdier et al., “Chemical speciation of vanadium in particulate matter emitted from diesel vehicles and urban atmospheric aerosols,” Environmental Science and Technology, vol. 46, no. 1, pp. 189–195, 2012. View at: Publisher Site | Google Scholar
  2. T. Kiss, E. Kiss, E. Garribba, and H. Sakurai, “Speciation of insulin-mimetic VO(IV)-containing drugs in blood serum,” Journal of Inorganic Biochemistry, vol. 80, no. 1-2, pp. 65–73, 2000. View at: Publisher Site | Google Scholar
  3. R. Yanardag, S. Bolkent, Ö. Karabulut-Bulan, and S. Tunali, “Effects of vanadyl sulfate on kidney in experimental diabetes,” Biological Trace Element Research, vol. 95, no. 1, pp. 73–85, 2003. View at: Publisher Site | Google Scholar
  4. M. Koyuturk, S. Tunali, S. Bolkent, and R. Yanardag, “Effects of vanadyl sulfate on liver of streptozotocin-induced diabetic rats,” Biological Trace Element Research, vol. 104, no. 3, pp. 233–247, 2005. View at: Publisher Site | Google Scholar
  5. Y. Niu, W. Liu, C. Tian et al., “Effects of bis(α-furancarboxylato)oxovanadium(IV) on glucose metabolism in fat-fed/streptozotocin-diabetic rats,” European Journal of Pharmacology, vol. 572, no. 2-3, pp. 213–219, 2007. View at: Publisher Site | Google Scholar
  6. D. Wei, M. Li, and W. Ding, “Effect of vanadate on gene expression of the insulin signaling pathway in skeletal muscle of streptozotocin-induced diabetic rats,” Journal of Biological Inorganic Chemistry, vol. 12, no. 8, pp. 1265–1273, 2007. View at: Publisher Site | Google Scholar
  7. M. Li, J. J. Smee, W. Ding, and D. C. Crans, “Anti-diabetic effects of sodium 4-amino-2,6-dipicolinatodioxovanadium(V) dihydrate in streptozotocin-induced diabetic rats,” Journal of Inorganic Biochemistry, vol. 103, no. 4, pp. 585–589, 2009. View at: Publisher Site | Google Scholar
  8. K. H. Thompson, J. Lichter, C. LeBel, M. C. Scaife, J. H. McNeill, and C. Orvig, “Vanadium treatment of type 2 diabetes: a view to the future,” Journal of Inorganic Biochemistry, vol. 103, no. 4, pp. 554–558, 2009. View at: Publisher Site | Google Scholar
  9. V. Badmaev, S. Prakash, and M. Majeed, “Vanadium: a review of its potential role in the fight against diabetes,” Journal of Alternative and Complementary Medicine, vol. 5, no. 3, pp. 273–291, 1999. View at: Google Scholar
  10. M. C. Cam, R. W. Brownsey, and J. H. McNeill, “Mechanisms of vanadium action: insulin-mimetic or insulin-enhancing agent?” Canadian Journal of Physiology and Pharmacology, vol. 78, no. 10, pp. 829–847, 2000. View at: Publisher Site | Google Scholar
  11. H. A. Sakurai, K. Tsuchiya, M. Nukatsuka, M. Sofue, and J. Kawada, “Insulin-like effect of vanadyl ion on streptozotocin-induced diabetic rats,” Journal of Endocrinology, vol. 126, no. 3, pp. 451–459, 1990. View at: Google Scholar
  12. M. T. Conconi, E. Decarlo, S. Vigolo et al., “Effects of some vanadyl coordination compounds on the in vitro insulin release from rat pancreatic islets,” Hormone and Metabolic Research, vol. 35, no. 7, pp. 402–406, 2003. View at: Publisher Site | Google Scholar
  13. Y. Shechter, I. Goldwaser, M. Mironchik, M. Fridkin, and D. Gefel, “Historic perspective and recent developments on the insulin-like actions of vanadium; toward developing vanadium-based drugs for diabetes,” Coordination Chemistry Reviews, vol. 237, no. 1-2, pp. 3–11, 2003. View at: Publisher Site | Google Scholar
  14. N. Venkatesan, A. Avidan, and M. B. Davidson, “Antidiabetic action of vanadyl in rats independent of in vivo insulin-receptor kinase activity,” Diabetes, vol. 40, no. 4, pp. 492–498, 1991. View at: Publisher Site | Google Scholar
  15. E. Tsiani and I. G. Fantus, “Vanadium compounds: biological actions and potential as pharmacological agents,” Trends in Endocrinology and Metabolism, vol. 8, no. 2, pp. 51–58, 1997. View at: Publisher Site | Google Scholar
  16. S. Verma, M. C. Cam, and J. H. McNeill, “Nutritional factors that can favorably influence the glucose/insulin system: vanadium,” Journal of the American College of Nutrition, vol. 17, no. 1, pp. 11–18, 1998. View at: Publisher Site | Google Scholar
  17. D. Rehder, “Biological and medicinal aspects of vanadium,” Inorganic Chemistry Communications, vol. 6, no. 5, pp. 604–617, 2003. View at: Publisher Site | Google Scholar
  18. M. Bendayan and D. Gingras, “Effect of vanadate administration on blood glucose and insulin levels as well as on the exocrine pancreatic function in streptozotocin-diabetic rats,” Diabetologia, vol. 32, no. 8, pp. 561–567, 1989. View at: Google Scholar
  19. G. A. Dehghani, M. Sotoodeh, and G. R. Omrani, “Trophic effects of vanadium on beta-cells of STZ-induced insulin-dependent diabetic rats and evidence for long term relief of diabetes mellitus,” Indian Journal of Medical Research, vol. 110, pp. 70–75, 1999. View at: Google Scholar
  20. A. K. Srivastava, “Anti-diabetic and toxic effects of vanadium compounds,” Molecular and Cellular Biochemistry, vol. 206, no. 1-2, pp. 177–182, 2000. View at: Publisher Site | Google Scholar
  21. J. J. Mongold, G. H. Cros, L. Vian et al., “Toxicological aspects of vanadyl sulphate on diabetic rats: effects on vanadium levels and pancreatic B-cell morphology,” Pharmacology and Toxicology, vol. 67, no. 3, pp. 192–198, 1990. View at: Publisher Site | Google Scholar
  22. J. Yao, M. L. Battell, and J. H. McNeill, “Acute and chronic response to vanadium following two methods of streptozotocin-diabetes induction,” Canadian Journal of Physiology and Pharmacology, vol. 75, no. 2, pp. 83–90, 1997. View at: Publisher Site | Google Scholar
  23. K. Akgün-Dar, S. Bolkent, R. Yanardag, and S. Tunali, “Vanadyl sulfate protects against streptozotocin-induced morphological and biochemical changes in rat aorta,” Cell Biochemistry and Function, vol. 25, no. 6, pp. 603–609, 2007. View at: Google Scholar
  24. S. Bolkent, S. Bolkent, R. Yanardag, and S. Tunali, “Protective effect of vanadyl sulfate on the pancreas of streptozotocin-induced diabetic rats,” Diabetes Research and Clinical Practice, vol. 70, no. 2, pp. 103–109, 2005. View at: Publisher Site | Google Scholar
  25. C. E. Heyliger, A. G. Tahiliani, and J. H. McNeill, “Effect of Vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats,” Science, vol. 227, no. 4693, pp. 1474–1477, 1985. View at: Publisher Site | Google Scholar
  26. G. A. Dehghani, S. Ahmadi, and G. R. Omrani, “Effects of vanadyl sulphate on glucose homeostasis in severe diabetes induced by streptozotocin in rats,” Indian Journal of Medical Research, vol. 106, pp. 481–485, 1997. View at: Google Scholar
  27. E. Shafrir, S. Spielman, I. Nachliel, M. Khamaisi, H. Bar-On, and E. Ziv, “Treatment of diabetes with vanadium salts: general overview and amelioration of nutritionally induced diabetes in the Psammomys obesus gerbil,” Diabetes/Metabolism Research and Reviews, vol. 17, no. 1, pp. 55–66, 2001. View at: Google Scholar
  28. M. Huang, Y. Wu, N. Wang, Z. Wang, Yang X., and P. Zhao, “Is the hypoglycemic action of vanadium compounds related to the suppression of feeding?” Biological Trace Element Research, vol. 157, no. 3, pp. 242–248, 2014. View at: Google Scholar
  29. M. Xie, D. Chen, F. Zhang, G. R. Willsky, D. C. Crans, and W. Ding, “Effects of vanadium (III, IV, V)-chlorodipicolinate on glycolysis and antioxidant status in the liver of STZ-induced diabetic rats,” Journal of Inorganic Biochemistry, vol. 136, pp. 47–56, 2014. View at: Publisher Site | Google Scholar
  30. M. Soveid, G. A. Dehghani, and G. R. Omrani, “Long- term efficacy and safety of vanadium in the treatment of type 1 diabetes,” Archives of Iranian Medicine, vol. 16, no. 7, pp. 408–411, 2013. View at: Google Scholar
  31. J. Meyerovitch, Z. Farfel, J. Sack, and Y. Shechter, “Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. Characterization and mode of action,” Journal of Biological Chemistry, vol. 262, no. 14, pp. 6658–6662, 1987. View at: Google Scholar
  32. A. B. Goldfine, D. C. Simonson, F. Folli, M. E. Patti, and C. R. Kahn, “In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus,” Molecular and Cellular Biochemistry, vol. 153, pp. 217–231, 1995. View at: Google Scholar
  33. M. C. Cam, B. Rodrigues, and J. H. McNeill, “Distinct glucose lowering and beta cell protective effects of vanadium and food restriction in streptozotocin-diabetes,” European Journal of Endocrinology, vol. 141, no. 5, pp. 546–554, 1999. View at: Publisher Site | Google Scholar
  34. G. Vardatsikos, M. Z. Mehdi, and A. K. Srivastava, “Bis(maltolato)-oxovanadium (IV)-induced phosphorylation of PKB, GSK-3 and FOXO1 contributes toits glucoregulatory responses,” International Journal of Molecular Medicine, vol. 24, no. 3, pp. 303–309, 2009. View at: Publisher Site | Google Scholar
  35. D. C. Crans, J. J. Smee, E. Gaidamauskas, and L. Yang, “The chemistry and biochemistry of vanadium and the biological activities exerted by vanadium compounds,” Chemical Reviews, vol. 104, no. 2, pp. 849–902, 2004. View at: Publisher Site | Google Scholar
  36. T. Scior, J. A. Guevara-García, F. J. Melendez, H. H. Abdallah, Q. T. Do, and P. Bernard, “Chimeric design, synthesis, and biological assays of a new nonpeptide insulin-mimetic vanadium compound to inhibit protein tyrosine phosphatase 1B,” Drug Design, Development and Therapy, vol. 4, pp. 231–242, 2010. View at: Google Scholar
  37. T. Scior, H. Mack, J. A. G. García, and W. Koch, “Antidiabetic bis-maltolato-oxovanadium(IV): conversion of inactive trans- to bioactive cis-BMOV for possible binding to target PTP-1B,” Drug Design, Development and Therapy, vol. 2, pp. 221–231, 2008. View at: Google Scholar
  38. A. Mohammad, V. Sharma, and J. H. McNeill, “Vanadium increases GLUT4 in diabetic rat skeletal muscle,” Molecular and Cellular Biochemistry, vol. 233, no. 1-2, pp. 139–143, 2002. View at: Publisher Site | Google Scholar
  39. S. Semiz and J. H. McNeill, “Oral treatment with vanadium of Zucker fatty rats activates muscle glycogen synthesis and insulin-stimulated protein phosphatase-1 activity,” Molecular and Cellular Biochemistry, vol. 236, no. 1-2, pp. 123–131, 2002. View at: Publisher Site | Google Scholar
  40. A. Ijaz, T. Tejada, P. Catanuto et al., “Inhibition of C-jun N-terminal kinase improves insulin sensitivity but worsens albuminuria in experimental diabetes,” Kidney International, vol. 75, no. 4, pp. 381–388, 2009. View at: Google Scholar
  41. A. B. Goldfine, M. E. Patti, L. Zuberi et al., “Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies,” Metabolism, vol. 49, no. 3, pp. 400–410, 2000. View at: Google Scholar
  42. S. Ahmadi, S. M. Karimian, M. Sotoudeh, M. Bahadori, and G. A. Dehghani, “Pancreatic islet beta cell protective effect of oral vanadyl sulphate in streptozotocin -induced diabetic rats, an ultrastructure study,” Pakistan Journal of Biological Sciences, vol. 13, no. 23, pp. 1135–1140, 2010. View at: Publisher Site | Google Scholar
  43. M. Waguri, K. Yamamoto, J. Miyagawa et al., “Demonstration of two different processes of β-cell regeneration in a new diabetic mouse model induced by selective perfusion of alloxan,” Diabetes, vol. 46, no. 8, pp. 1281–1290, 1997. View at: Publisher Site | Google Scholar

Copyright © 2014 Samira Missaoui et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.